Lisa Fischer is a European Registered Toxicologist (ERT) with more than 20 years of professional experience in nonclinical drug development, focusing on nonclinical safety/toxicology and strategic regulatory aspects.

She is Head of the ZH3D Academy and Nonclinical Drug Development Expert at the Zurich Hub for Drug and Device Development (ZH3D) University of Zurich. As the founder and Managing Director of Fischer PreclinTox Consulting, she advises biotech start-ups on nonclinical drug development.

Previously, she worked as a Study Director for toxicology studies at RCC Ltd., a Swiss GLP-certified contract research organization, as a Nonclinical Assessor and GLP Inspector at Swissmedic (Swiss Agency for Therapeutic Products), and as an Expert in Nonclinical Efficacy and Safety at ETH Zurich, where she also gained experience as a lecturer.

As Swissmedic’s representative, she was a member of the ICH S11 Expert Working Group and contributed to the development of the ICH S11 Guideline on “Nonclinical safety testing in support of development of paediatric pharmaceuticals”.